Vesselon, Inc. ("Vesselon") announced that effective today, Parviz Ghahramani Ph.D., Pharm.D., M.Sc., MBA has been appointed its Senior Executive Vice President, Head of Research and Development. Ghahramani will oversee Vesselon’s clinical research and product development, with a key focus on advancing commercialization initiatives for the biotech firm.
Ghahramani is the founder of Inncelerex and continues in that role. Inncelerex is a multi-faceted Drug Development Consultancy company, with a highly accomplished team of professionals each with over 27 years of expertise in clinical pharmacology, modeling and simulation, and early drug development. Throughout his career, Ghahramani has played pivotal roles in leadership and strategic positions within top pharmaceutical companies, including Pfizer, Roche, AstraZeneca, and Allergan (formerly Forest Laboratories). His contributions have been instrumental in steering more than 86 drug development projects across diverse stages, encompassing small molecules, biologics, and antibodies. Ghahramani and his team at Inncelerex will be supporting the development of the Vesselon platform.
Vesselon has pioneered a transformative co-formulation method that dramatically enhances drug bioavailability while creating new patentable entities for each drug, without modifying its active compound. Utilizing its Imagent® lipid microspheres — originally FDA-approved for contrast ultrasound — Vesselon’s TriForm™ co-formulation encapsulates drugs in gas microspheres and simultaneously generates drug-encapsulated self-assembling liposomes in the vial at the bedside. This allows specific and focal activation of the drug at and inside the tumor significantly enhancing anti-tumor effect at the intended site.
“Parviz brings tremendous knowledge and experience in drug development from his successful career in the industry, making him an exceptional choice to lead our R&D efforts," said Vesselon President and CEO, Clayton Larsen. “His proven track record of bringing innovative solutions to market and navigating the complexities of the drug discovery and regulatory landscape further solidifies his role as the right strategic leader for Vesselon.”
Ghahramani's significant industry impact is evident through his involvement in 31 New Drug Applications (NDA), Marketing Authorization Applications (MAA), and Japanese New Drug Applications (JNDA). He has been at the forefront of regulatory meetings, including Advisory Committee interactions and preparation of briefing books, specifically in the domains of Clinical Pharmacology and Modeling & Simulation.
His extensive experience spans multiple therapeutic areas, demonstrating proficiency in oncology, CNS, anti-infectives, drug-device combinations, diabetes, GI, and respiratory treatments. Ghahramani has been a driving force behind more than 308 licensing and acquisition assessments, as well as company mergers, showcasing his strategic vision and business acumen.
Ghahramani also commented the Vesselon platform has the potential to transform the pharmacokinetics for multiple classes of drugs. "I am looking forward to bringing this new field of pharmacology to the clinic and then rapidly into widespread practice,” he said.
Beyond his corporate endeavors, Ghahramani has actively contributed to the scientific community with over 130 publications in distinguished international journals. He has taken on advisory roles for organizations contributing to the pharmaceutical landscape such as the European Society for Translational Medicine (ESTM) and the International Drug Discovery Science and Technology. His commitment to giving back to the profession is reflected in his affiliation as a Professor at the University of Maryland.
Vesselon develops patentable drug co-formulations using an FDA-approved, biophysically activated lipid microsphere and self-assembling liposomes. These co-formulations safely make targeted tissues more receptive to therapeutic drugs, producing unprecedented levels of efficacy. For more information visit www.Vesselon.com.